Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by lonc17on Dec 16, 2023 8:58pm
328 Views
Post# 35788535

RE:RE:Many unknowns, one thing we know for sure

RE:RE:Many unknowns, one thing we know for sureItntdf,

Andrew De G. did in fact exercise his options last month, but there was a data entry omission in SEDI.

He should have recorded -100,000 for his options and then shown a corresponding +100,000 for ownership of common shares.

This would bring his total holdings of common shares to 110,315, not the half million or so that you had noted (those were his unexpired options before exiting the company).

Regardless, after exercising his options he holds more shares than both the CEO and CFO.  Good for him, he must have seen some promise in the company that the top guys fail to recognize.

Also, those $1.45 options are unusual because at the time of issue (2019) they were issued to only MC and Andrew De G.  That's weird.

I'm not sure which to be more annoyed by at this moment. The idea that MC thinks $1.45 CDN is too rich of a price to buy ONC or the fact that Andrew De G. left the company and it has not been reported to the market. Surely, this is a significant event and it appears that ONC is negligent in its duties as a publicly traded company.





<< Previous
Bullboard Posts
Next >>